J Am Soc Nephrol. 2004;15:761–9 [I].PubMedCrossRef 138. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;5:32 [I].PubMedCrossRef 139. Anderson SM, Park ZH, Patel RV. Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy. Ann Pharmacother. 2011;45:101–7 [I].PubMedCrossRef 140. Trivedi H. Is

Crenigacestat in vitro there enough evidence to support use of N-acetylcysteine in contrast-induced nephropathy? Ann Intern Med. 2008;149:213 (author reply 215–216 [VI]). 141. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407–10 [VI].PubMedCrossRef 142. Poletti PA, Saudan P,

Platon A, Mermillod B, Sautter AM, check details Vermeulen B, et al. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol. 2007;189:687–92 [VI].PubMedCrossRef 143. Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed selleck chemical tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009;84:170–9 [VI].PubMedCrossRef 144. Lanese DM, Yuan BH, Falk SA, Conger GABA Receptor JD. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am J Physiol. 1991;261:F1102–9 [VI].PubMed 145. Meyer-Lehnert H, Bayer T, Predel HG, Glanzer K, Kramer HJ. Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure. Klin Wochenschr. 1991;69:895–903 [VI].PubMedCrossRef 146. Valsson F, Ricksten SE, Hedner T, Lundin S. Effects of atrial natriuretic peptide on acute renal impairment in patients

with heart failure after cardiac surgery. Intensive Care Med. 1996;22:230–6 [IVa].PubMedCrossRef 147. Kurnik BR, Weisberg LS, Cuttler IM, Kurnik PB. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. J Lab Clin Med. 1990;116:27–36 [II].PubMed 148. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45:259–65 [II].PubMedCrossRef 149. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31:674–80 [II].PubMedCrossRef 150. Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009;53:1040–6 [II].PubMedCrossRef 151. Zhang J, Fu X, Jia X, Fan X, Gu X, Li S, et al.